Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Inogen, Inc. (INGN)

6.86 -0.40 (-5.51%)
At close: October 30 at 4:00:01 PM EDT
6.86 0.00 (0.00%)
After hours: October 30 at 4:00:16 PM EDT
Trade Inogen on Coinbase
Chart Range Bar
Loading chart for INGN
  • Previous Close 7.26
  • Open 7.30
  • Bid 5.23 x 200
  • Ask 6.90 x 100
  • Day's Range 6.69 - 7.30
  • 52 Week Range 5.05 - 8.29
  • Volume 201,105
  • Avg. Volume 305,946
  • Market Cap (intraday) 182.053M
  • Beta (5Y Monthly) 1.50
  • PE Ratio (TTM) --
  • EPS (TTM) -0.92
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 12.00
  • Motley Fool Rating Bearish

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.

www.provider.inogen.com

753

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

INGN
2.08%
S&P 500 (^GSPC)
10.73%

1-Year Return

INGN
16.03%
S&P 500 (^GSPC)
11.11%

3-Year Return

INGN
55.20%
S&P 500 (^GSPC)
81.91%

5-Year Return

INGN
82.70%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 95.08M
Earnings -3.85M
Profit Margin -4.05%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
20M
40M
60M
80M
-8.0%
-6.0%

Analyst Insights

View More

Analyst Price Targets

12.00
12.00 Average
6.86 Current
12.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/7/2026
Analyst Freedom Broker
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 12

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -6.94%

  • Return on Assets (ttm)

    -5.84%

  • Return on Equity (ttm)

    -13.14%

  • Revenue (ttm)

    354.3M

  • Net Income Avi to Common (ttm)

    -24.59M

  • Diluted EPS (ttm)

    -0.92

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    105.54M

  • Total Debt/Equity (mrq)

    9.03%

  • Levered Free Cash Flow (ttm)

    -1.77M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: